SLNO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Soleno Therapeutics (SLNO) is not a good buy for a long-term beginner investor at this time. The stock is trading near its acquisition price of $53, leaving minimal upside potential. Additionally, the company is facing multiple securities class action lawsuits, and its financial performance has significantly deteriorated in the latest quarter. Analysts have downgraded the stock due to the pending acquisition, and there are no strong proprietary trading signals to suggest a compelling entry point.
The stock is in an overbought condition with an RSI of 89.095. The MACD histogram is positive at 0.218, but it is contracting, indicating weakening momentum. The price is trading near resistance levels (R1: 52.795, R2: 52.878) with minimal room for further upside. Moving averages are converging, signaling a lack of clear trend direction.
The pending acquisition by Neurocrine Biosciences at $53 per share provides a floor to the stock price, reducing downside risk.
The company is facing multiple securities class action lawsuits related to undisclosed safety risks of its product DCCR. Analysts have downgraded the stock across the board due to the acquisition, and there is no expectation of a higher bid. Financial performance has deteriorated significantly, with net income and EPS showing steep declines.
In Q4 2025, revenue remained flat YoY at $91.73M. However, net income dropped by -176.71% YoY to $42.94M, and EPS fell by -156.69% YoY to 0.72. Gross margin remained strong at 99.06%, but overall financial performance indicates significant challenges.
Analysts have downgraded the stock to Neutral or Hold ratings with a price target of $53, citing the pending acquisition by Neurocrine Biosciences. There is no expectation of a superior bid, and the stock is unlikely to outperform.
